The Price of Rarity: How the Orphan Drug System Fails the Patients It Was Designed to Protect

A System Built With Good Intentions

In 1983, Congress passed the Orphan Drug Act with a straightforward goal: to incentivize pharmaceutical companies to develop treatments for rare diseases that would otherwise be commercially unviable. Before the law existed, fewer than 10 drugs had been approved for rare conditions in the entire previous decade. The financial math was simple and discouraging—why invest hundreds of millions in research for a drug that might only serve a few thousand patients?

The Act changed those economics by offering drug manufacturers a package of incentives: seven years of market exclusivity, tax credits covering up to 50 percent of clinical trial costs, expedited FDA review, and waived application fees. The policy worked, at least by one measure. Since 1983, the FDA has approved more than 600 orphan drugs. Patients with conditions that once had no treatment options now have them.

But a troubling gap has emerged between the existence of these medications and the ability of patients to actually access them. And that gap is, in large part, measured in dollars.

When a Pill Costs More Than a House

The pricing landscape for orphan drugs is unlike anything else in American healthcare. Annual treatment costs routinely exceed $100,000. Some therapies approach or surpass $1 million per year. A 2021 analysis published in the Journal of the American Medical Association found that the median annual cost of a newly approved orphan drug was approximately $180,000—more than three times the median cost of non-orphan specialty drugs.

For families affected by conditions such as spinal muscular atrophy, Gaucher disease, or certain forms of hereditary angioedema, these are not abstract statistics. They are the difference between treatment and deterioration.

Manufacturers defend these prices on the grounds of development economics. Recouping research and development investment across a patient population of perhaps 5,000 individuals requires a fundamentally different pricing model than a medication taken by millions. Clinical trials for rare diseases are expensive to run and difficult to recruit for. Regulatory pathways, while expedited, still require substantial scientific investment. These arguments are not without merit—but they are increasingly difficult to accept at face value when some orphan drug manufacturers have generated billions of dollars in revenue from a single product.

The Incentive Structure Under Scrutiny

Critics of the current system point to several patterns that suggest the orphan drug framework has drifted from its original purpose.

One of the most frequently cited concerns is the practice known as salami slicing—the process by which a manufacturer obtains separate orphan drug designations for multiple subtypes or indications of the same condition, effectively multiplying the exclusivity periods and tax benefits available for a single compound. A drug originally developed for one rare condition may accumulate orphan designations for several related conditions, each carrying its own set of regulatory incentives.

Another concern involves large pharmaceutical companies acquiring small biotech firms that hold orphan drug designations, then dramatically raising prices post-acquisition. In these cases, the original development risk was borne by smaller entities, but the pricing power is exercised by corporations with substantial resources.

The Government Accountability Office has examined these patterns and noted that some of the most commercially successful orphan drugs generate revenues that far exceed what would be required to recover development costs—raising legitimate questions about whether the incentive structure is calibrated appropriately.

The Insurance Labyrinth

For patients with rare diseases, navigating insurance coverage is frequently described as a second full-time job. Many orphan drugs are classified as specialty medications requiring prior authorization, step therapy protocols, or appeals processes that can take months—during which patients may go without treatment.

Medicare's coverage of orphan drugs varies depending on whether the medication is administered in a physician's office (Part B) or dispensed through a pharmacy (Part D), and the cost-sharing structures differ substantially between these pathways. For patients on fixed incomes, even after insurance, out-of-pocket costs can be prohibitive.

Medicaid coverage presents its own complications. While most state Medicaid programs are required to cover FDA-approved drugs, access to specific orphan drugs can be delayed or restricted through formulary management tools that create additional barriers for patients who are already medically vulnerable.

Patient Assistance Programs: A Lifeline With Limitations

Pharmaceutical manufacturers of orphan drugs frequently operate patient assistance programs (PAPs) that provide medications at reduced or no cost to qualifying patients. These programs are often not widely publicized, and awareness of their existence varies enormously among patients and even among healthcare providers.

The National Organization for Rare Disorders (NORD) maintains a database of patient assistance programs and also operates its own assistance fund for patients with rare diseases. The HealthWell Foundation and Patient Advocate Foundation similarly offer financial assistance for qualifying individuals. For patients enrolled in Medicare, the Extra Help program (also known as the Low Income Subsidy) can significantly reduce out-of-pocket prescription costs.

However, these programs are not a comprehensive solution. Eligibility requirements vary and often exclude patients whose income exceeds certain thresholds—thresholds that may still leave a family financially devastated by a $200,000 annual drug bill. Programs can also be discontinued at a manufacturer's discretion, leaving patients in a precarious position mid-treatment.

State pharmaceutical assistance programs exist in some states, and patient advocacy organizations specific to individual rare diseases often maintain the most current and detailed information about available resources. For patients navigating this landscape, connecting with a disease-specific advocacy organization early in the process can be invaluable.

What Reform Might Look Like

The debate over orphan drug pricing intersects with broader conversations about pharmaceutical pricing reform in the United States. Several proposals have gained traction in recent years, including tying drug prices to measures of clinical benefit, expanding Medicare's ability to negotiate prices for high-cost drugs, and revisiting the exclusivity provisions of the Orphan Drug Act to better distinguish between drugs that genuinely required extraordinary development investment and those that did not.

The Inflation Reduction Act of 2022 included provisions allowing Medicare to negotiate prices for certain high-cost drugs, though orphan drugs with a single rare disease indication were initially exempted from negotiation—a carve-out that patient advocates and policy analysts continue to debate.

Navigating the System Today

For patients and families facing the reality of a rare disease diagnosis right now, the policy debate offers cold comfort. The practical priorities are clear: work with your treating physician and a pharmacist experienced in specialty medications to understand all available options; contact the manufacturer's patient services department directly to ask about assistance programs; reach out to NORD or the relevant disease-specific patient organization; and if insurance denies coverage, initiate the appeals process immediately with support from your healthcare team.

The orphan drug system was designed to ensure that rarity would not be a death sentence. Ensuring that access to treatment is not determined solely by financial resources remains an unfinished obligation.